Monterey Bio Acquisition Corporation (Nasdaq: MTRYU) has officially rebranded as Monterey Innovation Acquisition Corp. on March 10, 2023. The company is shifting its acquisition strategy to focus on a wider array of disruptive technology targets. Significant changes to the board and management team include the addition of Chris Coleman, Jory Des Jardins, and Roderick Hardamon, along with Jonas Grossman as Executive Chairman. Murat Omur will take over as CEO and Sean McGann as CFO. With a new leadership team backed by extensive relationships, the company aims to identify and acquire a technology business suited for public markets.
Monterey Bio Acquisition Corporation announced that starting November 22, 2021, holders of units from its IPO can separately trade shares of common stock and warrants. Units will continue to trade under MTRYU, while separated shares and warrants will trade under MTRY and MTRYW, respectively. The SEC declared the registration statement effective on September 30, 2021.
The Company focuses on acquiring a biotech firm poised for growth in therapeutic development, particularly in oncology and immunology.
Monterey Bio Acquisition Corporation (Nasdaq: MTRYU) announced the closing of its initial public offering (IPO), raising $115 million by selling 10 million units at $10.00 each, with an added 1.5 million units from the underwriter's option. Each unit includes one share of common stock and one redeemable warrant, allowing purchase of additional shares at $11.50 each. The company's management team, led by CEO Sanjeev Satyal, aims to identify viable biotech acquisition targets, particularly in oncology and immunology.